Literature DB >> 11983230

Ex vivo detection and enumeration of human antigen-specific CD8+ T lymphocytes using antigen delivery by a recombinant vaccinia expression vector and intracellular cytokine staining.

Sue A Speller1, Andrew P Warren.   

Abstract

We describe an intracellular cytokine staining, flow cytometry based technique for quantitative and qualitative assessment of CD8+ T lymphocyte-mediated antigen specific immune responses. This adaptation of the technique first described by Suni et al. [J. Immunol. Methods, 212 (1998) 89; Cytometry, 40 (2000) 60] utilises a recombinant vaccinia expression vector to deliver the test antigen to the MHC class I processing pathway. This allows the measurement of antigen-specific CD8+ T cell responses in human subjects, irrespective of HLA type, and un-restricted to responses directed against a single peptide epitope. This method offers an advantage over the ELISPOT methods because the cells producing cytokine in the assay can be readily phenotyped, and it permits the simultaneous analysis of multiple cytokines. Finally, this technique does not require the prior establishment of autologous transformed B cell lines from patients/subjects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11983230     DOI: 10.1016/s0022-1759(02)00025-x

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells.

Authors:  Rama Rao Amara; Pragati Nigam; Sunita Sharma; Jinyan Liu; Vanda Bostik
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

2.  A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease.

Authors:  Rama Rao Amara; Kalpana Patel; Genevieve Niedziela; Pragati Nigam; Sunita Sharma; Silvija I Staprans; David C Montefiori; Lakshmi Chenareddi; James G Herndon; Harriet L Robinson; Harold M McClure; Francis J Novembre
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  An adaptation of recombinant vaccinia-based ELISPOT and intracellular cytokine staining for a comparative measurement of cellular immune responses in HIV-1 and HIV-2 infections in West Africa.

Authors:  A Eshofonie; M Shim van der Loeff; H Whittle; A Jaye
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

Review 4.  Vaccine therapies for patients with glioblastoma.

Authors:  Eli T Sayegh; Taemin Oh; Shayan Fakurnejad; Orin Bloch; Andrew T Parsa
Journal:  J Neurooncol       Date:  2014-08-28       Impact factor: 4.130

Review 5.  Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

Authors:  Ingo Drexler; Caroline Staib; Gerd Sutter
Journal:  Curr Opin Biotechnol       Date:  2004-12       Impact factor: 9.740

6.  DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge.

Authors:  Pragati Nigam; Patricia L Earl; Jeffrey L Americo; Sunita Sharma; Linda S Wyatt; Yvette Edghill-Spano; Lakshmi S Chennareddi; Peter Silvera; Bernard Moss; Harriet L Robinson; Rama Rao Amara
Journal:  Virology       Date:  2007-05-16       Impact factor: 3.513

7.  Interferon-gamma response of PBMC indicates productive pseudorabies virus (PRV) infection in swine.

Authors:  Bärbel Hoegen; Armin Saalmüller; Marlene Röttgen; Hanns-Joachim Rziha; Hermann Geldermann; Gerald Reiner; Eberhard Pfaff; Mathias Büttner
Journal:  Vet Immunol Immunopathol       Date:  2004-12-28       Impact factor: 2.046

8.  Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses.

Authors:  Melissa L Precopio; Michael R Betts; Janie Parrino; David A Price; Emma Gostick; David R Ambrozak; Tedi E Asher; Daniel C Douek; Alexandre Harari; Giuseppe Pantaleo; Robert Bailer; Barney S Graham; Mario Roederer; Richard A Koup
Journal:  J Exp Med       Date:  2007-05-29       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.